Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 177

Similar articles for PubMed (Select 22759480)

1.

Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials.

Tran HT, Liu Y, Zurita AJ, Lin Y, Baker-Neblett KL, Martin AM, Figlin RA, Hutson TE, Sternberg CN, Amado RG, Pandite LN, Heymach JV.

Lancet Oncol. 2012 Aug;13(8):827-37. doi: 10.1016/S1470-2045(12)70241-3. Epub 2012 Jul 2.

PMID:
22759480
2.

Phase II study of pazopanib as second-line treatment after sunitinib in patients with metastatic renal cell carcinoma: a Southern China Urology Cancer Consortium Trial.

Xie M, He CS, Huang JK, Lin QZ.

Eur J Cancer. 2015 Mar;51(5):595-603. doi: 10.1016/j.ejca.2015.01.005. Epub 2015 Jan 21.

PMID:
25618828
3.

A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma.

Zurita AJ, Jonasch E, Wang X, Khajavi M, Yan S, Du DZ, Xu L, Herynk MH, McKee KS, Tran HT, Logothetis CJ, Tannir NM, Heymach JV.

Ann Oncol. 2012 Jan;23(1):46-52. doi: 10.1093/annonc/mdr047. Epub 2011 Apr 4.

4.

Plasma cytokine and angiogenic factor profiling identifies markers associated with tumor shrinkage in early-stage non-small cell lung cancer patients treated with pazopanib.

Nikolinakos PG, Altorki N, Yankelevitz D, Tran HT, Yan S, Rajagopalan D, Bordogna W, Ottesen LH, Heymach JV.

Cancer Res. 2010 Mar 15;70(6):2171-9. doi: 10.1158/0008-5472.CAN-09-2533. Epub 2010 Mar 9.

5.

Kidney cancer: prognostic and predictive biomarkers for RCC emerge.

Razzak M.

Nat Rev Urol. 2012 Aug;9(8):412. doi: 10.1038/nrurol.2012.146. Epub 2012 Jul 24. No abstract available.

PMID:
22824777
6.

Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials.

Coppin C, Kollmannsberger C, Le L, Porzsolt F, Wilt TJ.

BJU Int. 2011 Nov;108(10):1556-63. doi: 10.1111/j.1464-410X.2011.10629.x. Epub 2011 Sep 27. Review.

PMID:
21952069
7.

Pazopanib for the treatment of metastatic renal cell carcinoma.

Pick AM, Nystrom KK.

Clin Ther. 2012 Mar;34(3):511-20. doi: 10.1016/j.clinthera.2012.01.014. Epub 2012 Feb 16. Review.

PMID:
22341567
8.

Phosphorylation of mTOR and S6RP predicts the efficacy of everolimus in patients with metastatic renal cell carcinoma.

Li S, Kong Y, Si L, Chi Z, Cui C, Sheng X, Guo J.

BMC Cancer. 2014 May 28;14:376. doi: 10.1186/1471-2407-14-376.

9.

Utilizing pre-therapy clinical schema and initial CT changes to predict progression-free survival in patients with metastatic renal cell carcinoma on VEGF-targeted therapy: a preliminary analysis.

Smith AD, Shah SN, Rini BI, Lieber ML, Remer EM.

Urol Oncol. 2013 Oct;31(7):1283-91. doi: 10.1016/j.urolonc.2011.08.010. Epub 2011 Sep 29.

PMID:
21956044
10.

Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma.

Suttle AB, Ball HA, Molimard M, Hutson TE, Carpenter C, Rajagopalan D, Lin Y, Swann S, Amado R, Pandite L.

Br J Cancer. 2014 Nov 11;111(10):1909-16. doi: 10.1038/bjc.2014.503. Epub 2014 Oct 28. Erratum in: Br J Cancer. 2014 Dec 9;111(12):2383.

PMID:
25349968
11.

Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial.

Motzer RJ, Escudier B, Tomczak P, Hutson TE, Michaelson MD, Negrier S, Oudard S, Gore ME, Tarazi J, Hariharan S, Chen C, Rosbrook B, Kim S, Rini BI.

Lancet Oncol. 2013 May;14(6):552-62. doi: 10.1016/S1470-2045(13)70093-7. Epub 2013 Apr 16. Erratum in: Lancet Oncol. 2013 Jun;14(7):e254.

PMID:
23598172
12.

Pazopanib: the newest tyrosine kinase inhibitor for the treatment of advanced or metastatic renal cell carcinoma.

Keisner SV, Shah SR.

Drugs. 2011 Mar 5;71(4):443-54. doi: 10.2165/11588960-000000000-00000. Review.

PMID:
21395357
13.

Tumour burden is an independent prognostic factor in metastatic renal cell carcinoma.

Iacovelli R, Lanoy E, Albiges L, Escudier B.

BJU Int. 2012 Dec;110(11):1747-53. doi: 10.1111/j.1464-410X.2012.11518.x. Epub 2012 Oct 26.

PMID:
23106948
14.

Pazopanib: in advanced renal cell carcinoma.

Sanford M, Keating GM.

BioDrugs. 2010 Oct 1;24(5):279-86. doi: 10.2165/11205480-000000000-00000. Review.

PMID:
20649181
15.

Biomarkers in personalised treatment of renal-cell carcinoma.

Shariat SF, Xylinas E.

Lancet Oncol. 2012 Aug;13(8):751-2. doi: 10.1016/S1470-2045(12)70292-9. Epub 2012 Jul 2. No abstract available.

PMID:
22759479
16.

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial.

Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, Barrios CH, Salman P, Gladkov OA, Kavina A, Zarbá JJ, Chen M, McCann L, Pandite L, Roychowdhury DF, Hawkins RE.

J Clin Oncol. 2010 Feb 20;28(6):1061-8. doi: 10.1200/JCO.2009.23.9764. Epub 2010 Jan 25.

17.

Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.

Choueiri TK, Garcia JA, Elson P, Khasawneh M, Usman S, Golshayan AR, Baz RC, Wood L, Rini BI, Bukowski RM.

Cancer. 2007 Aug 1;110(3):543-50.

18.

The role of aberrant VHL/HIF pathway elements in predicting clinical outcome to pazopanib therapy in patients with metastatic clear-cell renal cell carcinoma.

Choueiri TK, Fay AP, Gagnon R, Lin Y, Bahamon B, Brown V, Rosenberg JE, Hutson TE, Baker-Neblett KL, Carpenter C, Liu Y, Pandite L, Signoretti S.

Clin Cancer Res. 2013 Sep 15;19(18):5218-26. doi: 10.1158/1078-0432.CCR-13-0491. Epub 2013 Jul 23.

19.

Assessment of progression-free survival as a surrogate end-point for overall survival in patients with metastatic renal cell carcinoma.

Négrier S, Bushmakin AG, Cappelleri JC, Korytowsky B, Sandin R, Charbonneau C, Michaelson MD, Figlin RA, Motzer RJ.

Eur J Cancer. 2014 Jul;50(10):1766-71. doi: 10.1016/j.ejca.2014.03.012. Epub 2014 Apr 23.

20.

The outcome of patients treated with sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer.

Powles T, Blank C, Chowdhury S, Horenblas S, Peters J, Shamash J, Sarwar N, Boleti E, Sahdev A, O'Brien T, Berney D, Beltran L, Nathan P, Haanen J, Bex A.

Eur Urol. 2011 Sep;60(3):448-54. doi: 10.1016/j.eururo.2011.05.028. Epub 2011 May 17.

PMID:
21612860
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk